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Background. The control of severe bronchial asthma, such as corticosteroid-resistant asthma, is diﬃcult. It is also possible that
immunosuppressive agents would be eﬀective for bronchial asthma. Case Summary. A 55-year-old Japanese female presented
with severe bronchial asthma controlled with tacrolimus. She had been diagnosed with bronchial asthma during childhood. Her
asthma worsened, and a chest radiograph showed atelectasis of the left lung. Bronchoscopy revealed the left main bronchus
to be obstructed with viscous sputum consisting of 82% neutrophils and no eosinophils. The atelectasis did not improve with
corticosteroid treatment, but was ameliorated by administration of tacrolimus. Discussion. This patient had severe asthma due to
neutrophilicinﬂammationoftheairways.Tacrolimusiseﬀective fortreatingsevereasthma,forexample,incorticosteroid-resistant
cases.
1.Introduction
The control of severe bronchial asthma, such as cortico-
steroid-resistant asthma, is diﬃcult [1]. T cells are strongly
associated with bronchial asthma [2]. It has also been
suggestedthatimmunosuppressiveagentssuppressingTcells
would be eﬀective for the treatment of bronchial asthma [3].
Immunosuppressive agents have recently been administered
in rare cases of severe bronchial asthma.
This case report describes a patient suﬀering from severe
bronchial asthma, associated with airway inﬂammation due
to neutrophil inﬁltration, which could be controlled by the
administration of tacrolimus.
2.ClinicalSummary
A 55-year-old Japanese female was admitted with infected
traumatic cutaneous ulcers. The infectious organism was
Staphylococcus aureus, and levoﬂoxacin was administered.
She had been diagnosed with bronchial asthma during
childhood and had been treated by her family doctor. For
several years, her bronchial asthma worsened and she was
treated with ﬂuticasone/salmeterol (500mcg/100mcg per
day), prednisolone (10mg per day), theophylline (400mg
per day), and pranlukast (leukotriene receptor antagonist,
450mg per day). She had suﬀered from dyspnea upon exer-
tion and wheezing continuously for the prior two months.
Pulmonary function tests, which had been conducted three
months before admission, showed a pattern of obstruction
(Figure 1).
Her bronchial asthma showed exacerbation after admis-
sion. Laboratory studies revealed a serum lactate dehydroge-
nase(LDH)levelof287internationalunits(IU)perliter,my-
eloperoxidase-antineutrophil cytoplasmic antibody (MPO-
ANCA)levelsless than 1.3IU per milliliter, and an immuno-
globulin E (IgE) level of 635IU per milliliter; no peripheral
blood eosinophils were detected (Table 1). Her prednisolone
dose was increased to 20mg per day, but she developed
dyspnea, wheezing, and hypoxia necessitating inhalation of
oxygen. This exacerbation of her bronchial asthma persisted
for a month, despite the increase in prednisolone. Next,
300mg per day of omalizumab was administered; however,
her dyspnea persisted (Figure 2) and her chest radiograph
showed atelectasis of the left lung (Figure 3). Her CRP level
was 0.27mg per liter. Bronchoscopy revealed that the left
main bronchus and other left bronchi were obstructed with
colorless viscous sputum. Due to the large volume of viscous
sputum in the peripheral bronchi, bronchial toileting did2 Journal of Allergy
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Figure 1: The results of the pulmonary function tests three months before admission.
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Figure 2: The clinical course. (SFC: ﬂuticasone/salmeterol, LVFX: levoﬂoxacin, and PAPM/BP: panipenem/betamipron.)
not improve the atelectasis. No eosinophils or malignant
cells were identiﬁed in suction specimens of the sputum,
which contained 82% neutrophils and 18% lymphocytes,
and no bacteria or fungi were detected by sputum cultures.
The prednisolone dose was increased to 120mg per day for
three days and then to 60mg per day for the remainder
of the hospitalization. Panipenem/betamipron (carbapenem
antibiotic) was administered concurrently with the pred-
nisolone treatment for two weeks. However, the patient
continued to demonstrate severe dyspnea, wheezing, and
hypoxia that required the inhalation of a large amount of
oxygen,andheratelectasisdidnotimprove.Onemonthlater,
she was treated with 2mg per day of tacrolimus. Her symp-
toms and respiratory status did not change during the ﬁrstJournal of Allergy 3
Figure 3: A chest radiograph showed atelectasis of the left lung.
Figure 4: A chest radiograph showed an improvement in the
atelectasis of the left lung.
week, but, thereafter, the atelectasis improved (Figure 4).
Thereafter, her dyspnea and hypoxia started to gradually
improve. After three months of tacrolimus administration,
oxygen administration was stopped and the patient became
capable of short walks. The prednisolone was tapered over
the course of four weeks to 20mg per day, and she was
transferred to another hospital for rehabilitation.
3.Discussion
In the current patient, we suspected that the cause of
atelectasis was exacerbation of bronchial asthma. This case
was not considered to have allergic bronchopulmonary as-
pergillosis based on negative ﬁndings for IgE speciﬁc to
aspergillus, negative suction sputum cultures, no peripheral
blood eosinophils, and no central bronchiectasis. We also
Table 1: Laboratory data obtained at the start of the exacerbation
ofbronchialasthma.(UniCAPspeciﬁcIgE:Fluoroenzymeimmuno-
analyses speciﬁc immunoglobulinE.)
Hematology
White blood cells 14,500/mm3
Neutrophils 91.0%
Eosinophils 0.0%
Lymphocytes 6.0%
Monocytes 3.0%
Basophils 0.0%
Red blood cells 396×104/mm3
Hemoglobin 11.5 g/dl
Hematocrit 33.9%
Platelets 25.1×10
4/mm3
Biochemistry
Total protein 5.1 g/dl
Albumin 3.3g/dl
Lactate dehydrogenase 287IU/l
Aspartate aminotransferase 10IU/l
Alanine aminotransferase 16IU/l
Creatin phosphokinase 21IU/l
Blood urea nitrogen 6mg/dl
Creatinine 0.3mg/dl
Fasting blood suger 116mg/dl
Serology
C-reactive protein 0.28mg/dl
Myeloperoxidase-antineutrophil
cytoplasmic autoantibodies <10EU
Antinuclear antibodies negative
Immunoglobulin E 635IU/ml
Aspergillus antigen (−)
Candida antigen (−)
UniCAP speciﬁc Immunoglobulin E
Dermatophagoides farinae <0.34UA/ml
Dermatophagoides farinae <0.34UA/ml
House dust 1 <0.34UA/ml
House dust 2 0.45UA/ml
Aspergillus <0.34UA/ml
Candida 22.30UA/ml
ruled out the possibility of allergic bronchopulmonary
candidiasis, becausethe onlypositive ﬁnding was IgEspeciﬁc
to candida. In addition, there were no signs of bacterial
infection in her lungs, as demonstrated by negative serum
CRP, negative suction sputum specimen cultures, and a lack
of response to antibiotic treatment.
The basic pathology of bronchial asthma is chronic
airway inﬂammation with inﬁltration of inﬂammatory cells
such as eosinophils. Asthmatics with severe disease have
predominantly neutrophilic inﬂammation, in contrast to
asthmaticswhosediseaseiscontrolled[4,5].Thesigniﬁcance
of neutrophilicinﬂammation is not apparent, butwhen such4 Journal of Allergy
inﬂammation is not controlled by corticosteroid therapy,
there is an association with increased severity in a subset
of severe asthma cases. The current patient’s suction spu-
tum specimens, which were obtained during bronchoscopy,
included many neutrophils but no eosinophils. Therefore,
the patient demonstrated severe asthma due to neutrophilic
inﬂammation.
Tacrolimus is an immunosuppressive agent. This drug
has a mode of action which is similar to that of cyclosporine,
namelyduetoitsabilitytoinhibitcalcineurininTcells.Some
previous studies on humans regarding steroid-dependent
asthma treated with oral cyclosporine have been reported [6,
7].These results,therefore,suggestthatcyclosporinmight be
beneﬁcial in some patients with steroid-dependent asthma,
while not being of any beneﬁt in other patients.
Tacrolimus suppresses the activation of T cells [8]a n d
the production of interleukin (IL)-2, IL-3, IL-4, IL-5, IL-
6[ 9], granulocyte/macrophage colony-stimulating factor
(GM-CSF) [10], interferon-gamma, and other proteins.
Tacrolimus is thought to control severe asthma by sup-
pressing the activation of T cells [2]. In this case, severe
asthma was not controlled only with tacrolimus but also
by many other treatments administered prior to tacrolimus.
Tacrolimus would have provided additional beneﬁts. Helper
Tlymphocytesplayaveryimportant roleinthedevelopment
and progression of asthma [2], and these T lymphocytes
probably played a similar role in this case. In our patient,
tacrolimusmayhavecontrolledsevereasthmabysuppressing
Tcellacti vation[2],which would resultinthesuppressionof
airway inﬂammation. It is followed by that narrowing of the
airways, hypersecretion of inspissated mucus, as well as air-
way mucosal capacity for excretion of mucus, all improved.
As a result, the viscous sputum in the left bronchus
and other left bronchi disappeared and atelectasis thereby
improved. However, neutrophils were the predominant cell
type associated with airway inﬂammation in our patient.
Neutrophilsare activated by multiple factors, including IL-6,
IL-8, leukotriene B4, and GM-CSF [11]. It may also be that
tacrolimus controls severe asthma by suppressing the activa-
tion of neutrophils via the suppression of IL-6 expression or
by some other as yet unknown mechanisms. GM-CSF sup-
presses the activation of neutrophils, but strongly activates
eosinophils. Moreover, it is interesting that corticosteroid
therapy prolongs neutrophil survival and accelerates neu-
trophilic airway inﬂammation by preventing apoptosis [12].
We have presented a case of severe bronchial asthma,
associated with airway inﬂammation characterized by neu-
trophil inﬁltration, controlled with tacrolimus. Therefore,
this drug should be considered for the treatment of severe
asthma, including cases demonstrating corticosteroid resis-
tance.
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